Everest Medicines Announces Substantial Shareholder CBC Group's Increase in Shareholding

Shanghai, China -- May 22, 2026 -- Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that its substantial shareholder, CBC Group, purchased 600,500 ordinary shares of the Company on the market from 20 May 2026 to 21 May 2026. The total consideration for this transaction was approximately HK$19.2 million, representing an average price of approximately HK$31.91 per Share.

This purchase represents a further increase in CBC Group's shareholding in the Company. Since December 2025, CBC Group and the Directors have purchased more than 3,062,000 Shares on the market for a total consideration of more than HK$113.8 million in aggregate. The Board believes that the purchases reflect the firm confidence of the Directors and the substantial shareholder of the Company in the future prospects and long-term development of the Company. In compliance with the applicable laws and regulations, CBC Group and the Directors do not rule out the possibility of further increasing their shareholdings in the Company when appropriate.



About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.

Forward-Looking Statements
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.